Farnesoid X receptor (FXR) from normal to malignant state

Histology and Histopathology

Volumn 27, Issue 7, 2012, Pages 835-853

  Koutsounas, Ioannis ^a   Giaginis, Constantinos ^a   Theocharis, Stamatios ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Bile acids; Carcinogenesis; Cholestasis; Farnesoid X receptor; Inflammation

Indexed keywords

CELL RECEPTOR; FARNESOID X RECEPTOR; FARNESOID X-ACTIVATED RECEPTOR;

ANIMAL; CELL TRANSFORMATION; DRUG ANTAGONISM; DRUG EFFECT; GENE EXPRESSION REGULATION; HUMAN; METABOLISM; MOUSE; PHYSIOLOGY; REVIEW;

ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE; RECEPTORS, CYTOPLASMIC AND NUCLEAR;

BACTERIA (MICROORGANISMS); MUS;

EID: 84861910852     PISSN: 02133911     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (119)

1. Alberts D.S., Hallum A.V. 3rd, Stratton-Custis M., Garcia D.J., Gleason-Guzman M., Salmon S.E., Santabarbara P., Niesor E.J., Floret S. and Bentzen C.L. (2001). Phase I pharmacokinetic trial and correlative in vitro phase II tumor kinetic study of Apomine (SR-45023A), a novel oral biphosphonate anticancer drug. Clin. Cancer Res. 7, 1246-1250.
2. Ananthanarayanan M., Balasubramanian N., Makishima M., Mangelsdorf D.J. and Suchy F.J. (2001). Human bile salt export pump promoter is transactivated by the farnesoid X receptor/bile acid receptor. J. Biol. Chem. 276, 28857-28865.
3. Au-Yeung K.K., Liu, P.L., Chan C., Wu W.Y., Lee S.S. and Ko J.K. (2008). Herbal isoprenols induce apoptosis in human colon cancer cells through transcriptional activation of PPARgamma. Cancer Invest. 26, 708-717.
4. Bergheim I., Harsch S., Mueller O., Schimmel S., Fritz P. and Stange E.F. (2006). Apical sodium bile acid transporter and ileal lipid binding protein in gallstone carriers. J. Lipid Res. 47, 42-50.
5. Bernstein H., Bernstein C., Payne C.M. and Dvorak K. (2009). Bile acids as endogenous etiologic agents in gastrointestinal cancer. World J. Gastroenterol. 15, 3329-3340.
6. Burke Y.D., Ayoubi A.S., Werner S.R., McFarland B.C., Heilman D.K., Ruggeri B.A. and Crowell P.L. (2002). Effects of the isoprenoids perillyl alcohol and farnesol on apoptosis biomarkers in pancreatic cancer chemoprevention. Anticancer Res. 22, 3127-3134.
7. Capello A., Moons L.M., Van de Winkel A., Siersema P.D., van Dekken H., Kuipers E.J. and Kusters J.G. (2008). Bile acid-stimulated expression of the farnesoid X receptor enhances the immune response in Barrett esophagus. Am. J. Gastroenterol. 103, 1510-1516.
8. Cariou B., van Harmelen K., Duran-Sandoval D., van Dijk T.H., Grefhorst A., Abdelkarim M., Caron S., Torpier G., Fruchart J.C., Gonzalez F.J., Kuipers F. and Staels B. (2006). The farnesoid X receptor modulates adiposity and peripheral insulin sensitivity in mice. J. Biol. Chem. 281, 11039-11049.
9. Catalano S., Malivindi R., Giordano C., Gu G., Panza S., Bonofiglio D., Lanzino M., Sisci D., Panno M.L. and Ando S. (2010). Farnesoid X receptor, through the binding with steroidogenic factor 1-responsive element, inhibits aromatase expression in tumor Leydig cells. J. Biol. Chem. 285, 5581-5593.
10. Chawla A., Repa J.J., Evans R.M. and Mangelsdorf D.J. (2001). Nuclear receptors and lipid physiology: opening the X-files. Science 294, 1866-1870.
11. Chen W.D., Wang Y.D., Zhang L., Shiah S., Wang M., Yang F., Yu D., Forman B.M. and Huang W. (2010). Farnesoid X receptor alleviates age-related proliferation defects in regenerating mouse livers by activating forkhead box m1b transcription. Hepatology 51, 953-962.
12. Chignard N. and Poupon R. (2009). Targeting farnesoid x receptor in hepatic and biliary inflammatory diseases. Gastroenterology 137, 734-735.
13. Cipriani S., Mencarelli A., Palladino G. and Fiorucci S. (2010). FXR activation reverses insulin resistance and lipid abnormalities and protects against liver steatosis in Zucker (fa/fa) obese rats. J. Lipid Res. 51, 771-784.
14. Claudel T., Sturm E., Duez, H., Torra I.P., Sirvent A., Kosykh V., Fruchart J.C., Dallongeville J., Hum D.W., Kuipers F. and Staels B. (2002). Bile acid-activated nuclear receptor FXR suppresses apolipoprotein A-I transcription via a negative FXR response element. J. Clin. Invest. 109, 961-971.
15. Costarelli V. and Sanders T.A. (2002). Plasma deoxycholic acid concentration is elevated in postmenopausal women with newly diagnosed breast cancer. Eur. J. Clin. Nutr. 56, 925-927.
16. D'Aldebert E., Biyeyeme Bi Mve M.J., Mergey M., Wendum D., Firrincieli D., Coilly A., Fouassier L., Corpechot C., Poupon R., Housset C. and Chignard N. (2009). Bile salts control the antimicrobial peptide cathelicidin through nuclear receptors in the human biliary epithelium. Gastroenterology 136, 1435-1443.
17. De Gottardi A., Touri F., Maurer C.A., Perez A., Maurhofer O., Ventre G., Bentzen C.L., Niesor E.J. and Dufour J.F. (2004). The bile acid nuclear receptor FXR and the bile acid binding protein IBABP are differently expressed in colon cancer. Dig. Dis. Sci. 49, 982-989.
18. De Gottardi A., Dumonceau J.M., Bruttin F., Vonlaufen A., Morard I., Spahr L., Rubbia-Brandt L., Frossard J.L., Dinjens W.N., Rabinovitch P.S. and Hadengue A. (2006). Expression of the bile acid receptor FXR in Barrett's esophagus and enhancement of apoptosis by guggulsterone in vitro. Mol. Cancer 5, 48.
19. Debruyne P.R., Bruyneel E.A., Li X., Zimber A., Gespach C. and Mareel M.M. (2001). The role of bile acids in carcinogenesis. Mutat. Res. 480-481, 359-369.
20. Debruyne P.R., Bruyneel E.A., Karaguni I.M., Li X., Flatau G., Muller O., Zimber A., Gespach C. and Mareel M.M. (2002). Bile acids stimulate invasion and haptotaxis in human colorectal cancer cells through activation of multiple oncogenic signaling pathways. Oncogene 21, 6740-6750.
21. Demars C.J., Buttar N.S., Fiorucci S., Anderson M.A., Papenfuss S.M., Lutzke L.S. and Wang K.K. (2005). Farnesoid-X-receptor and carcinogenesis in Barrett's esophagus. Proc. Amer. Assoc. Cancer Res. 46, 1343-b, Abstractnr 5713.
22. Duran-Sandoval D., Mautino G., Martin G., Percevault F., Barbier O., Fruchart J.C., Kuipers F. and Staels B. (2004). Glucose regulates the expression of the farnesoid X receptor in liver. Diabetes 53, 890-898.
23. Fang C., Dean J. and Smith J.W. (2007). A novel variant of ileal bile acid binding protein is up-regulated through nuclear factor-kappaB activation in colorectal adenocarcinoma. Cancer Res. 67, 9039-9046.
24. Fickert P., Zollner G., Fuchsbichler A., Stumptner C., Weiglei A.H., Lammert F., Marschall H.U., Tsybrovskyy O., Zatloukal K., Denk H. and Trauner M. (2002). Ursodeoxycholic acid aggravates bile infarcts in bile duct-ligated and Mdr2 knockout mice via disruption of cholangioles. Gastroenterology 123, 1238-1251.
25. Fiorucci S., Antonelli E., Rizzo G., Renga B., Mencarelli A., Riccardi, L., Orlandi S., Pellicciari R. and Morelli, A. (2004). The nuclear receptor SHP mediates inhibition of hepatic stellate cells by FXR and protects against liver fibrosis. Gastroenterology 127, 1497-1512.
26. Fiorucci S., Clerici C., Antonelli E., Orlandi S., Goodwin B., Sadeghpour B.M., Sabatino G., Russo G., Castellani D., Willson T.M., Pruzanski M., Pellicciari R. and Morelli A. (2005). Protective effects of 6-ethyl chenodeoxycholic acid, a farnesoid X receptor ligand, in estrogen-induced cholestasis. J. Pharmacol. Exp. Ther. 313, 604-612.
27. Flach J., Antoni I., Villemin P., Bentzen C.L. and Niesor E.J. (2000). The mevalonate/isoprenoid pathway inhibitor apomine (SR-45023A) is antiproliferative and induces apoptosis similar to farnesol. Biochem. Biophys. Res. Commun. 270, 240-246.
28. Frankenberg T., Miloh T., Chen F.Y., Ananthanarayanan M., Sun A.Q., Balasubramaniyan N., Arias, I., Setchell, K.D., Suchy F.J. and Shneider B.L. (2008). The membrane protein ATPase class I type 8B member 1 signals through protein kinase C zeta to activate the farnesoid X receptor. Hepatology 48, 1896-1905.
29. Gadaleta R.M., van Mil S.W., Oldenburg B., Siersema P.D., Klomp L. W. and van Erpecum K.J. (2010). Bile acids and their nuclear receptor FXR: Relevance for hepatobiliary and gastrointestinal disease. Biochim. Biophys. Acta 1801, 683-692.
30. Gadaleta R.M., Oldenburg B., Willemsen E.C., Spit M., Murzilli S., Salvatore L., Klomp L.W., Siersema P.D., van Erpecum K.J. and van Mil S.W. (2011a). Activation of bile salt nuclear receptor FXR is repressed by pro-inflammatory cytokines activating NF-kappaB signaling in the intestine. Biochim. Biophys. Acta 1812, 851-858.
31. Gadaleta R.M., van Erpecum K.J., Oldenburg B., Willemsen E.C., Renooij W., Murzilli S., Klomp L.W., Siersema P.D., Schipper M.E., Danese S., Penna G., Laverny G., Adorini L., Moschetta A. and van Mil S.W. (2011b). Farnesoid X receptor activation inhibits inflammation and preserves the intestinal barrier in inflammatory bowel disease. Gut 60, 463-472.
32. Hanniman E.A., Lambert G., McCarthy T.C. and Sinal C.J. (2005). Loss of functional farnesoid X receptor increases atherosclerotic lesions in apolipoprotein E-deficient mice. J. Lipid Res. 46, 2595-2604.
33. Harada K. and Nakanuma Y. (2010). Biliary innate immunity in the pathogenesis of biliary diseases. Inflamm. Allergy Drug Targets 9, 83-90.
34. He N., Park K., Zhang Y., Huang J., Lu S. and Wang L. (2008). Epigenetic inhibition of nuclear receptor small heterodimer partner is associated with and regulates hepatocellular carcinoma growth. Gastroenterology 134, 793-802.
35. Holt J.A., Luo G., Billin A.N., Bisi J., McNeill Y.Y., Kozarsky K.F., Donahee M., Wang D.Y., Mansfield T.A., Kliewer S.A., Goodwin B. and Jones S.A. (2003). Definition of a novel growth factor-dependent signal cascade for the suppression of bile acid biosynthesis. Genes Dev. 17, 1581-1591.
36. Howard W.R., Pospisil J.A., Njolito E. and Noonan D.J. (2000). Catabolites of cholesterol synthesis pathways and forskolin as activators of the farnesoid X-activated nuclear receptor. Toxicol. Appl. Pharmacol. 163, 195-202.
37. Huang L., Zhao A., Lew J.L., Zhang T., Hrywna Y., Thompso J.R., de Pedro N., Royo I., Blevins R.A., Pelaez F., Wright S.D. and Cui J. (2003). Farnesoid X receptor activates transcription of the phospholipid pump MDR3. J. Biol. Chem. 278, 51085-51090.
38. Huang W., Ma K., Zhang, J., Qatanani M., Cuvillier J., Liu J., Dong B., Huang X. and Moore D.D. (2006). Nuclear receptor-dependent bile acid signaling is required for normal liver regeneration. Science 312, 233-236.
39. Inagaki T., Choi M., Moschetta A., Peng L., Cummins C.L., McDonald J.G., Luo G., Jones S.A., Goodwin B., Richardson J.A., Gerard R.D., Repa J.J., Mangelsdorf D.J. and Kliewer S.A. (2005). Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. Cell Metab. 2, 217-225.
40. Inagaki T., Moschetta A., Lee Y.K., Peng L., Zhao G., Downes M., Yu R.T., Shelton J.M., Richardson J.A., Repa J.J., Mangelsdorf D.J. and Kliewer S.A. (2006). Regulation of antibacterial defense in the small intestine by the nuclear bile acid receptor. Proc. Natl. Acad. Sci. USA 103, 3920-3925.
41. Insull W. Jr (2006). Clinical utility of bile acid sequestrants in the treatment of dyslipidemia: a scientific review. South Med. J. 99, 257-273.
42. Jemal A., Bray F., Center M.M., Ferlay J., Ward E. and Forman D. (2011). Global cancer statistics. CA Cancer J. Clin. 61, 69-90.
43. Joo J.H. and Jetten A.M. (2010). Molecular mechanisms involved in farnesol-induced apoptosis. Cancer Lett. 287, 123-135.
44. Joo J.H., Liao G., Collins J.B., Grissom S.F. and Jetten A.M. (2007). Farnesol-induced apoptosis in human lung carcinoma cells is coupled to the endoplasmic reticulum stress response. Cancer Res. 67, 7929-7936.
45. Journe F., Laurent G., Chaboteaux C., Nonclercq D., Durbecq V., Larsimont D. and Body J.J. (2008). Farnesol, a mevalonate pathway intermediate, stimulates MCF-7 breast cancer cell growth through farnesoid-X-receptor-mediated estrogen receptor activation. Breast Cancer Res. Treat. 107, 49-61.
46. Journe F., Durbecq V., Chaboteaux C., Rouas G., Laurent G., Nonclercq D., Sotiriou C., Body J.J. and Larsimont D. (2009). Association between farnesoid X receptor expression and cell proliferation in estrogen receptor-positive luminal-like breast cancer from postmenopausal patients. Breast Cancer Res. Treat. 115, 523-535.
47. Jung D., Podvinec M., Meyer U.A., Mangelsdorf D.J., Fried M., Meier P. J. and Kullak-Ublick G.A. (2002). Human organic anion transporting polypeptide 8 promoter is transactivated by the farnesoid X receptor/bile acid receptor. Gastroenterology 122, 1954-1966.
48. Kaeding J., Bouchaert E., Belanger J., Caron P., Chouinard S., Verreault M., Larouche O., Pelletier G., Staels B., Belanger A. and Barbier O. (2008). Activators of the farnesoid X receptor negatively regulate androgen glucuronidation in human prostate cancer LNCAP cells. Biochem. J. 410, 245-253.
49. Kast H.R., Goodwin B., Tarr P.T., Jones S.A., Anisfeld A.M., Stoltz C.M., Tontonoz P., Kliewer S., Willson T.M. and Edwards P.A. (2002). Regulation of multidrug resistance-associated protein 2 (ABCC2) by the nuclear receptors pregnane X receptor, farnesoid X-activated receptor, and constitutive androstane receptor. J. Biol. Chem. 277, 2908-2915.
50. Katona B.W., Anant S., Covey D.F. and Stenson W.F. (2009). Characterization of enantiomeric bile acid-induced apoptosis in colon cancer cell lines. J. Biol. Chem. 284, 3354-3364.
51. Kim I., Morimura K., Shah Y., Yang, Q., Ward, J.M. and Gonzalez F.J. (2007). Spontaneous hepatocarcinogenesis in farnesoid X receptor-null mice. Carcinogenesis 28, 940-946.
52. Kim N.D., Im E., Yoo Y.H. and Choi Y.H. (2006). Modulation of the cell cycle and induction of apoptosis in human cancer cells by synthetic bile acids. Curr. Cancer Drug Targets 6, 681-689.
53. Kjoller L. and Hall A. (2001). Rac mediates cytoskeletal rearrangements and increased cell motility induced by urokinase-type plasminogen activator receptor binding to vitronectin. J. Cell Biol. 152, 1145-1157.
54. Komichi D., Tazuma S., Nishioka T., Hyogo H. and Chayama K. (2005). A nuclear receptor ligand down-regulates cytosolic phospholipase A2 expression to reduce bile acid-induced cyclooxygenase 2 activity in cholangiocytes: implications of anticarcinogenic action of farnesoid X receptor agonists. Dig. Dis. Sci. 50, 514-524.
55. Kounalakis N., Lau S., Darling D., Smith D., Palomares M. and Lai L. (2009). The nuclear receptor FXR links metabolism with breast cancer. Cancer Res. 69 (24 Suppl), Abstractnr 5153.
56. Krishnamurthy K., Wang G., Rokhfeld D. and Bieberich E. (2008). Deoxycholate promotes survival of breast cancer cells by reducing the level of pro-apoptotic ceramide. Breast Cancer Res. 10, R106.
57. Laffitte B.A., Kast H.R., Nguyen C.M., Zavacki A.M., Moore D.D. and Edwards P.A. (2000). Identification of the DNA binding specificity and potential target genes for the farnesoid X-activated receptor. J. Biol. Chem. 275, 10638-10647.
58. Lambert G., Amar M.J., Guo G., Brewer H.B. Jr, Gonzalez F.J. and Sinal C.J. (2003). The farnesoid X-receptor is an essential regulator of cholesterol homeostasis. J. Biol. Chem. 278, 2563-2570.
59. Langhi C., Le May C., Kourimate S., Caron S., Staels B., Krempf M., Costet P. and Cariou B. (2008). Activation of the farnesoid X receptor represses PCSK9 expression in human hepatocytes. FEBS Lett. 582, 949-955.
60. Lee F.Y., Lee H., Hubbert M.L., Edwards P.A. and Zhang Y. (2006). FXR, a multipurpose nuclear receptor. Trends Biochem. Sci. 31, 572-580.
61. Lee J.Y., Lee K.T., Lee J.K., Lee K.H., Jang K.T., Heo J.S., Choi S.H., Kim Y. and Rhee J.C. (2011). Farnesoid X receptor, overexpressed in pancreatic cancer with lymph node metastasis promotes cell migration and invasion. Br. J. Cancer 104, 1027-1037.
62. Lefebvre P., Cariou B., Lien F., Kuipers F. and Staels B. (2009). Role of bile acids and bile acid receptors in metabolic regulation. Physiol. Rev. 89, 147-191.
63. Lewis K.D., Thompson J.A., Weber J.S., Robinson W.A., O'Day S., Lutzky J., Legha S.S., Floret S., Ruvuna F. and Gonzalez R. (2006). A phase II open-label trial of apomine (SR-45023A) in patients with refractory melanoma. Invest. New Drugs 24, 89-94.
64. Liu Y., Binz J., Numerick M.J., Dennis S., Luo G., Desai B., MacKenzie K.I., Mansfield T.A., Kliewer S.A., Goodwin B. and Jones S.A. (2003). Hepatoprotection by the farnesoid X receptor agonist GW4064 in rat models of intra- and extrahepatic cholestasis. J. Clin. Invest. 112, 1678-1687.
65. Lowe L.C., Senaratne S.G. and Colston K.W. (2005). Induction of apoptosis in breast cancer cells by apomine is mediated by caspase and p38 mitogen activated protein kinase activation. Biochem. Biophys. Res. Commun. 329, 772-779.
66. Ma K., Saha P.K., Chan L. and Moore D.D. (2006). Farnesoid X receptor is essential for normal glucose homeostasis. J. Clin. Invest. 116, 1102-1109.
67. Maran R.R., Thomas A., Roth M., Sheng Z., Esterly N., Pinson D., Gao X., Zhang Y., Ganapathy V., Gonzalez F.J. and Guo G.L. (2009). Farnesoid X receptor deficiency in mice leads to increased intestinal epithelial cell proliferation and tumor development. J. Pharmacol. Exp. Ther. 328, 469-477.
68. Mariette C., Perrais M., Leteurtre E., Jonckheere N., Hemon B., Pigny P., Batra S., Aubert J.P., Triboulet J.P. and Van Seuningen I. (2004). Transcriptional regulation of human mucin MUC4 by bile acids in oesophageal cancer cells is promoter-dependent and involves activation of the phosphatidylinositol 3-kinase signalling pathway. Biochem. J. 377, 701-708.
69. Matsukuma K.E., Bennett M.K., Huang J., Wang L., Gil G. and Osborne T.F. (2006). Coordinated control of bile acids and lipogenesis through FXR-dependent regulation of fatty acid synthase. J. Lipid Res. 47, 2754-2761.
70. Mencarelli A., Renga B., Migliorati M., Cipriani S., Distrutti E., Santucci L. and Fiorucci S. (2009). The bile acid sensor farnesoid X receptor is a modulator of liver immunity in a rodent model of acute hepatitis. J. Immunol. 183, 6657-6666.
71. Modica S., Murzilli S., Salvatore L., Schmidt D.R. and Moschetta A. (2008). Nuclear bile acid receptor FXR protects against intestinal tumorigenesis. Cancer Res. 68, 9589-9594.
72. Modica S., Gofflot F., Murzilli S., D'Orazio A., Salvatore L., Pellegrini F., Nicolucci A., Tognoni G., Copetti M., Valanzano R., Veschi S., Mariani-Costantini R., Palasciano G., Schoonjans K., Auwerx J. and Moschetta A. (2010). The intestinal nuclear receptor signature with epithelial localization patterns and expression modulation in tumors. Gastroenterology 138, 636-648.
73. Monte M.J., Fernandez-Tagarro M., Macias R.I., Jimenez F., Gonzalez-San Martin F. and Marin J.J. (2005). Changes in the expression of genes related to bile acid synthesis and transport by the rat liver during hepatocarcinogenesis. Clin. Sci. (Lond.) 109, 199-207.
74. Moschetta A., Bookout A.L. and Mangelsdorf D.J. (2004). Prevention of cholesterol gallstone disease by FXR agonists in a mouse model. Nat. Med. 10, 1352-1358.
75. National Institutes of Health (NIH), Clinical Trials. Available at http://www.clinicaltrials.gov.
76. Neimark E., Chen F., Li X. and Shneider B.L. (2004). Bile acid-induced negative feedback regulation of the human ileal bile acid transporter. Hepatology 40, 149-156.
77. Niesor E.J., Flach J., Lopes-Antoni I., Perez A. and Bentzen C.L. (2001). The nuclear receptors FXR and LXRalpha: potential targets for the development of drugs affecting lipid metabolism and neoplastic diseases. Curr. Pharm. Des. 7, 231-259.
78. Ong T.P., Heidor R., de Conti A., Dagli M.L. and Moreno F.S. (2006). Farnesol and geraniol chemopreventive activities during the initial phases of hepatocarcinogenesis involve similar actions on cell proliferation and DNA damage, but distinct actions on apoptosis, plasma cholesterol and HMGCoA reductase. Carcinogenesis 27, 1194-1203.
79. Park S.E., Choi H.J., Yee S.B., Chung H.Y., Suh H., Choi Y.H., Yoo Y.H. and Kim N.D. (2004). Synthetic bile acid derivatives inhibit cell proliferation and induce apoptosis in HT-29 human colon cancer cells. Int. J. Oncol. 25, 231-236.
80. Park Y.Y., Choi H.S. and Lee J.S. (2010). Systems-level analysis of gene expression data revealed NR0B2/SHP as potential tumor suppressor in human liver cancer. Mol. Cells 30, 485-491.
81. Pourpak A., Dorr R.T., Meyers R.O., Powell M.B. and Stratton S.P. (2007). Cytotoxic activity of Apomine is due to a novel membrane-mediated cytolytic mechanism independent of apoptosis in the A375 human melanoma cell line. Invest. New Drugs 25, 107-114.
82. Pullinger C.R., Eng C., Salen G., Shefer S., Batta A. K., Erickson S.K., Verhagen A., Rivera C.R., Mulvihill S.J., Malloy M.J. and Kane J.P. (2002). Human cholesterol 7alpha-hydroxylase (CYP7A1) deficiency has a hypercholesterolemic phenotype. J. Clin. Invest. 110, 109-117.
83. Rabbani S.A. and Xing R.H. (1998). Role of urokinase (uPA) and its receptor (uPAR) in invasion and metastasis of hormone-dependent malignancies. Int. J. Oncol. 12, 911-920.
84. Raimondi S., Maisonneuve P. and Lowenfels A.B. (2009). Epidemiology of pancreatic cancer: an overview. Nat. Rev. Gastroenterol. Hepatol. 6, 699-708.
85. Renner O., Harsch S., Strohmeyer A., Schimmel S. and Stange E.F. (2008). Reduced ileal expression of OSTalpha-OSTbeta in non-obese gallstone disease. J. Lipid Res. 49, 2045-2054.
86. Sahin M.B., Perman S.M., Jenkins G. and Clark S.S. (1999). Perillyl alcohol selectively induces G0/G1 arrest and apoptosis in Bcr/Abl-transformed myeloid cell lines. Leukemia 13, 1581-1591.
87. Scheper M.A., Shirtliff M.E., Meiller T.F., Peters B.M. and Jabra-Rizk M.A. (2008). Farnesol, a fungal quorum-sensing molecule triggers apoptosis in human oral squamous carcinoma cells. Neoplasia 10, 954-963.
88. Schmidt D.R., Schmidt S., Holmstrom S.R., Makishima M., Yu R.T., Cummins C.L., Mangelsdorf D.J. and Kliewer S.A. (2011). AKR1B7 is induced by the farnesoid X receptor and metabolizes bile acids. J. Biol. Chem. 286, 2425-2432.
89. Shih D.M., Kast-Woelbern H.R., Wong J., Xia Y.R., Edwards P.A. and Lusis A.J. (2006). A role for FXR and human FGF-19 in the repression of paraoxonase-1 gene expression by bile acids. J. Lipid Res. 47, 384-392.
90. Silva J., Dasgupta S., Wang G., Krishnamurthy K., Ritter E. and Bieberich E. (2006). Lipids isolated from bone induce the migration of human breast cancer cells. J. Lipid Res. 47, 724-733.
91. Sinal C.J., Tohkin M., Miyata M., Ward J.M., Lambert G. and Gonzalez F.J. (2000). Targeted disruption of the nuclear receptor FXR/BAR impairs bile acid and lipid homeostasis. Cell 102, 731-744.
92. Smith D.L., Keshavan P., Avissar U., Ahmed K. and Zucker S.D. (2010). Sodium taurocholate inhibits intestinal adenoma formation in APCMin/+ mice, potentially through activation of the farnesoid X receptor. Carcinogenesis 31, 1100-1109.
93. Staels B. and Kuipers F. (2007). Bile acid sequestrants and the treatment of type 2 diabetes mellitus. Drugs 67, 1383-1392.
94. Swales K.E., Korbonits M., Carpenter R., Walsh D.T., Warner T.D. and Bishop-Bailey D. (2006). The farnesoid X receptor is expressed in breast cancer and regulates apoptosis and aromatase expression. Cancer Res. 66, 10120-10126.
95. van de Winkel A., van Zoest K.P., van Dekken H., Moons L.M., Kuipers E.J. and van der Laan L.J. (2011). Differential expression of the nuclear receptors farnesoid X receptor (FXR) and pregnane X receptor (PXR) for grading dysplasia in patients with Barrett's oesophagus. Histopathology 58, 246-253.
96. Van Mil S.W., Milona A., Dixon P.H., Mullenbach R., Geenes V.L., Chambers J., Shevchuk V., Moore G.E., Lammert F., Glantz A.G., Mattsson L.A., Whittaker J., Parker M.G., White R. and Williamson C. (2007). Functional variants of the central bile acid sensor FXR identified in intrahepatic cholestasis of pregnancy. Gastroenterology 133, 507-516.
97. Vavassori P., Mencarelli A., Renga B., Distrutti E. and Fiorucci S. (2009). The bile acid receptor FXR is a modulator of intestinal innate immunity. J. Immunol. 183, 6251-6261.
98. Verreault M., Kaeding J., Caron P., Trottier J., Grosse L., Houssin E., Paquet S., Perreault M. and Barbier O. (2010). Regulation of endobiotics glucuronidation by ligand-activated transcription factors: physiological function and therapeutic potential. Drug Metab. Rev. 42, 110-122.
99. Wachs F.P., Krieg R.C., Rodrigues C.M., Messmann H., Kullmann F., Knuchel-Clarke R., Scholmerich J., Rogler G. and Schlottmann K. (2005). Bile salt-induced apoptosis in human colon cancer cell lines involves the mitochondrial transmembrane potential but not the CD95 (Fas/Apo-1) receptor. Int. J. Colorectal Dis. 20, 103-113.
100. Wagner M., Fickert P., Zollner G., Fuchsbichler A., Silbert D., Tsybrovskyy O., Zatloukal K., Guo G.L., Schuetz J.D., Gonzalez F.J., Marschall H.U., Denk H. and Trauner M. (2003). Role of farnesoid X receptor in determining hepatic ABC transporter expression and liver injury in bile duct-ligated mice. Gastroenterology 125, 825-838.
101. Wang Y., Jones P.J., Woollett L.A., Buckley D.D., Yao L., Granholm N.A., Tolley E.A. and Heubi J.E. (2006). Effects of chenodeoxycholic acid and deoxycholic acid on cholesterol absorption and metabolism in humans. Transl. Res. 148, 37-45.
102. Wang Y.D., Chen W.D., Moore D.D. and Huang W. (2008a). FXR: a metabolic regulator and cell protector. Cell Res. 18, 1087-1095.
103. Wang Y.D., Chen W.D., Wang M., Yu D., Forman B.M. and Huang W. (2008b). Farnesoid X receptor antagonizes nuclear factor kappaB in hepatic inflammatory response. Hepatology 48, 1632-1643.
104. Wang Y.D., Yang F., Chen W.D., Huang X., Lai L., Forman B.M. and Huang W. (2008c). Farnesoid X receptor protects liver cells from apoptosis induced by serum deprivation in vitro and fasting in vivo. Mol. Endocrinol. 22, 1622-1632.
105. Watanabe M., Houten S.M., Wang L., Moschetta A., Mangelsdorf D.J., Heyman R.A., Moore D.D. and Auwerx J. (2004). Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c. J. Clin. Invest. 113, 1408-1418.
106. Wiseman D.A., Werner S.R. and Crowell P.L. (2007). Cell cycle arrest by the isoprenoids perillyl alcohol, geraniol, and farnesol is mediated by p21(Cip1) and p27(Kip1) in human pancreatic adenocarcinoma cells. J. Pharmacol. Exp. Ther. 320, 1163-1170.
107. Wu T. (2005). Cyclooxygenase-2 and prostaglandin signaling in cholangiocarcinoma. Biochim. Biophys. Acta 1755, 135-150.
108. Xu Y., Watanabe T., Tanigawa T., Machida H., Okazaki H., Yamagami H., Watanabe K., Tominaga K., Fujiwara Y., Oshitani N. and Arakawa T. (2010). Bile acids induce cdx2 expression through the farnesoid x receptor in gastric epithelial cells. J. Clin. Biochem. Nutr. 46, 81-86.
109. Yamada T., Osawa S., Hamaya Y., Furuta T., Hishida, A., Kajimura M. and Ikuma M. (2010). Guggulsterone suppresses bile acid-induced and constitutive caudal-related homeobox 2 expression in gut-derived adenocarcinoma cells. Anticancer Res. 30, 1953-1960.
110. Yang F., Huang X., Yi T., Yen Y., Moore D.D. and Huang W. (2007). Spontaneous development of liver tumors in the absence of the bile acid receptor farnesoid X receptor. Cancer Res. 67, 863-867.
111. Yen C.J., Izzo J.G., Lee D.F., Guha S., Wei Y., Wu T.T., Chen C.T., Kuo H.P., Hsu J.M., Sun H.L., Chou C.K., Buttar N.S., Wang K.K., Huang P., Ajani J. and Hung M.C. (2008). Bile acid exposure up-regulates tuberous sclerosis complex 1/mammalian target of rapamycin pathway in Barrett's-associated esophageal adenocarcinoma. Cancer Res. 68, 2632-2640.
112. Yoon J.H., Higuchi H., Werneburg N.W., Kaufmann S.H. and Gores G.J. (2002). Bile acids induce cyclooxygenase-2 expression via the epidermal growth factor receptor in a human cholangiocarcinoma cell line. Gastroenterology 122, 985-993.
113. Yu S.G., Hildebrandt L.A. and Elson C.E. (1995). Geraniol, an inhibitor of mevalonate biosynthesis, suppresses the growth of hepatomas and melanomas transplanted to rats and mice. J. Nutr. 125, 2763-2767.
114. Yui S., Saeki T., Kanamoto R. and Iwami K. (2005). Characteristics of apoptosis in HCT116 colon cancer cells induced by deoxycholic acid. J. Biochem. 138, 151-157.
115. Zhang Y., Kast-Woelbern H.R. and Edwards P.A. (2003). Natural structural variants of the nuclear receptor farnesoid X receptor affect transcriptional activation. J. Biol. Chem. 278, 104-110.
116. Zhang Y., Wang X., Vales C., Lee F.Y., Lee H., Lusis A.J. and Edwards P.A. (2006). FXR deficiency causes reduced atherosclerosis in Ldlr-/- mice. Arterioscler. Thromb. Vasc. Biol. 26, 2316-2321.
117. Zhang Q., He F., Kuruba R., Gao X., Wilson A., Li J., Billiar T.R., Pitt B.R., Xie W. and Li S. (2008a). FXR-mediated regulation of angiotensin type 2 receptor expression in vascular smooth muscle cells. Cardiovasc. Res. 77, 560-569.
118. Zhang Y., Xu P., Park K., Choi Y., Moore D.D. and Wang L. (2008b). Orphan receptor small heterodimer partner suppresses tumorigenesis by modulating cyclin D1 expression and cellular proliferation. Hepatology 48, 289-298.
119. Zhang S., Wang J., Liu Q. and Harnish D.C. (2009). Farnesoid X receptor agonist WAY-362450 attenuates liver inflammation and fibrosis in murine model of non-alcoholic steatohepatitis. J. Hepatol. 51, 380-388.